GSK and Spero Therapeutics Receive FDA Approval for First Oral Carbapenem Antibiotic for Complicated UTIs
GlaxoSmithKline (GSK) and Spero Therapeutics received U.S. Food and Drug Administration approval for Utebzi, the first oral carbapenem antibiotic to treat complicated urinary tract infections in adults. The drug is intended for patients with limited or no alternative oral treatment options.
Tickers: $GSK
Topics: antibiotics carbapenem complicated UTIs drug approval